We are live on ! Find out more
ZBIO

Zenas BioPharma
ZBIO

73 hedge funds and large institutions have $330M invested in Zenas BioPharma in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 12

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

29% more capital invested

Capital invested by funds: $257M → $330M (+$73.3M)

9% more funds holding

Funds holding: 67 → 73 (+6)

3.66% more ownership

Funds ownership: 77.75% → 81.41% (+3.7%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
73
Holders Change
+6
Holders Change %
+8.96%
% of All Funds
0.96%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
11
Increased
34
Reduced
12
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$6.85M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.59M
3
Citadel Advisors
Citadel Advisors
Florida
+$2.86M
4
SAM
Sectoral Asset Management
Quebec, Canada
+$2.05M
5
NMC
NEA Management Company
Maryland
+$1.17M

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$2.32M
2
EP
Eversept Partners
New York
-$1.17M
3
CCM
Catalio Capital Management
New York
-$777K
4
JFG
Jefferies Financial Group
New York
-$348K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$316K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$47.6M – – –
ES
2
Enavate Sciences
California
$36.4M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$32.2M +$4.59M +471,163 +17%
NMC
4
NEA Management Company
Maryland
$26.5M +$1.17M +119,771 +5%
NHAS
5
Novo Holdings A/S
Denmark
$21.8M +$341K +35,033 +2%
FFM
6
Fairmount Funds Management
Pennsylvania
$18.3M – – –
Federated Hermes
7
Federated Hermes
Pennsylvania
$18M +$6.85M +703,838 +61%
NA
8
NVP Associates
California
$17.8M – – –
DM
9
Deerfield Management
New York
$15.1M – – –
VC
10
Vivo Capital
California
$11.5M – – –
BlackRock
11
BlackRock
New York
$10.6M +$794K +81,499 +8%
ACH
12
ArrowMark Colorado Holdings
Colorado
$10.6M -$29.5K -3,031 -0.3%
Vanguard Group
13
Vanguard Group
Pennsylvania
$9.61M +$159K +16,306 +2%
Wellington Management Group
14
Wellington Management Group
Massachusetts
$8.52M +$51.6K +5,295 +0.6%
PBPIA
15
Pivotal bioVenture Partners Investment Advisor
California
$7.55M +$413K +42,400 +6%
RSCM
16
Rock Springs Capital Management
Maryland
$6.21M -$2.32M -238,200 -27%
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$4.7M -$316K -32,404 -6%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$3.62M +$160K +16,461 +5%
EP
19
Eversept Partners
New York
$3.15M -$1.17M -120,109 -27%
State Street
20
State Street
Massachusetts
$3.01M +$429K +44,036 +17%
Citadel Advisors
21
Citadel Advisors
Florida
$2.85M +$2.86M +293,785 New
CCM
22
Catalio Capital Management
New York
$2.09M -$777K -79,834 -27%
SAM
23
Sectoral Asset Management
Quebec, Canada
$2.04M +$2.05M +210,625 New
Schroder Investment Management Group
24
Schroder Investment Management Group
United Kingdom
$1.48M -$88.8K -9,119 -6%
Morgan Stanley
25
Morgan Stanley
New York
$1.2M +$452K +46,391 +60%
1
2 3 4

ZBIO Hedge Fund Activity: Q2 2025 in Review

73 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Zenas BioPharma (ZBIO) for Q2 2025, worth a combined $330M — up 29% from $257M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ZBIO positions and 5 closed out — a net gain of 6 holders — while 34 added to existing stakes and 12 trimmed.

The largest buyer was Federated Hermes, adding an estimated $6.85M. The largest seller was Rock Springs Capital Management, cutting an estimated $2.32M.

  • 73 institutional investors held Zenas BioPharma (ZBIO) as of Q2 2025, up from 67 in Q1 2025.
  • Funds reported $330M of Zenas BioPharma stock for Q2 2025, up 29% quarter-over-quarter.
  • 11 funds opened new Zenas BioPharma positions in Q2 2025 and 5 closed out, a net change of +6 holders.
  • The largest Zenas BioPharma buyer in Q2 2025 was Federated Hermes, an estimated $6.85M added.
  • The largest Zenas BioPharma seller in Q2 2025 was Rock Springs Capital Management, an estimated $2.32M sold.

Based on aggregated 13F filings for Q2 2025.